Omacetaxine mepesuccinate


Thông tin thuốc gốc
Chỉ định và Liều dùng
Subcutaneous
Chronic myeloid leukaemia
Adult: Chronic or accelerated phase: Induction: 1.25 mg/m2 bid at approx 12-hour intervals for 14 consecutive days of a 28-day cycle, repeated every 28 days until haematological response is achieved. Maintenance: 1.25 mg/m2 bid for 7 consecutive days of a 28-day cycle, repeated as long as there is clinical benefit. Dose modifications may be required if toxicity occur.
Hướng dẫn pha thuốc
Add 1 mL of NaCl 0.9% to a vial labelled as containing 3.5 mg. Swirl gently until a clear solution is obtained.
Chống chỉ định
Pregnancy.
Thận trọng
Patient with diabetes or risk factors for diabetes. Lactation.
Phản ứng phụ
Significant: Gastrointestinal haemorrhage, glucose intolerance, hyperglycaemia.
Blood and lymphatic system disorders: Lymphopenia, bone marrow failure, febrile neutropenia.
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, constipation, abdominal pain.
General disorders and administration site conditions: Asthenia, fatigue, pyrexia, injection site reactions.
Metabolism and nutrition disorders: Anorexia, peripheral oedema.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain, myalgia, pain in extremity.
Nervous system disorders: Headache.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Cough, epistaxis.
Skin and subcutaneous tissue disorders: Alopecia, rash.
Potentially Fatal: Severe anaemia, neutropenia, and thrombocytopenia; cerebral haemorrhage.
Parenteral/SC: D
Thông tin tư vấn bệnh nhân
This drug may cause fatigue, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor CBC during induction and initial maintenance therapy then every 2 weeks thereafter or as clinically indicated; blood glucose frequently; signs of bleeding or infection.
Quá liều
Symptoms: Gastrointestinal disorders, gingival haemorrhage, alopecia, neutropenia, thrombocytopenia. Management: Supportive treatment.
Tương tác
Increased risk of haemorrhage with anticoagulants, aspirin, and other NSAIDS.
Tác dụng
Description: Omacetaxine mepesuccinate is a semisynthetic formulation of homoharringtonine, an alkaloid derived from Cephalotaxus harringtonia. It reversibly inhibits protein synthesis by binding to the A-site cleft of the ribosomal subunit.
Synonym: homoharringtonine.
Pharmacokinetics:
Absorption: Rapidly absorbed. Time to peak plasma concentration: Approx 30 minutes.
Distribution: Plasma protein binding: ≤50%.
Metabolism: Hydrolysed by plasma esterases to 4’-DMHHT. Minimal hepatic microsomal oxidative or esterase-mediated metabolism.
Excretion: Via urine (approx 37%) and faeces (approx 44%). Terminal elimination half-life: 14.6 hours.
Đặc tính

Chemical Structure Image
Omacetaxine mepesuccinate

Source: National Center for Biotechnology Information. PubChem Database. Omacetaxine mepesuccinate, CID=285033, https://pubchem.ncbi.nlm.nih.gov/compound/Omacetaxine-mepesuccinate (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C. Protect from light.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, administration, and disposal.
Phân loại MIMS
Phân loại ATC
L01XX40 - omacetaxine mepesuccinate ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
References
Anon. Omacetaxine Mepesuccinate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/05/2018.

Anon. Omacetaxine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/05/2018.

Buckingham R (ed). Omacetaxine Mepesuccinate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/05/2018.

Synribo Injection, Powder, Lyophilized, for Solution (Cephalon, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/05/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Omacetaxine mepesuccinate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in